Immunologic parameters and results of lung function tests in selected pulmonary diseases taking course with fibrosis
More details
Hide details
Z Kliniki Pneumonologii, Onkologii i Alergologii UM w Lublinie
Z Zakładu Badań Czynnościowych Instytutu Medycyny Wsi w Lublinie
Z Samodzielnego Publicznego Szpitala Klinicznego Nr 1 w Lublinie
Z Samodzielnej Pracowni Biologii Molekularnej Instytutu Medycyny Wsi im. W. Chodźki w Lublinie; Z Katedry Zdrowia Publicznego WyŜszej Szkoły Informatyki i Zarządzania w Rzeszowie
Z Kliniki Pneumonologii, Onkologii i Alergologii UM w Lublinie; Z Samodzielnej Pracowni Chorób Fibroproliferacyjnych Instytutu Medycyny Wsi im. W. Chodźki w Lublinie
Med Og. 2010;16(1):1-13
The objective of the study was the evaluation of the differences in diffusion capacity and spirometric test in patients with selected parenchymal lung diseases, and determination of the relationship observed in immune profile at the site of pathological process in progress with changes in lung function. Parenchymal lung disease was diagnosed in a group of 25 patients based on clinical, radiologic and histopathologic examinations. In addition, spirometric test was performed, and single-breath carbon monoxide diffusing capacity (DLCO) with the measurement of the total diffusing capacity of the whole lung and residual volume by the method of He dilution. In all the patients examined bronchoscopy was also performed with bronchoalveolar lavage, and the analysis of leukocyte phenotypes in bronchoalveolar lavage fluid by means of monoclonal antibodies with the use of flow cytometer. For all the groups analysed a statistically significant relationship was noted between the type of parenchymal disease diagnosed and reduction in lung diffusion capacity. In addition, significant positive correlations were confirmed between the percentage of macrophages in bronchoalveolar lavage fluid and alveolar flow, and between the percentage of T-helper lymphocytes and maximum expiratory flow.
American Thoracic Society. ATS/ERS international multidisciplinary consensus classification of idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000, 161, 646-664.
Boehler A., Vogt P., Speich R., Weder W., Russi EW.: Bronchiolitis obliterans in a patient with localized scleroderma treated with D-penicillamine. Eur Respir J., 1996, 6, 1317-1319.
Bouros D., Antoniou K.M.: Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J, 2005, 26, 693-702.
Choi K.H., Lee H.B., Jeong M.Y., Rhee Y.K., Chung M.J., Kwak Y.G., Lee Y.C.: The role of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in cryptogenic organizing pneumonia. Chest, 2002, 121, 5, 1478-1485.
Kim D.S., Collard H.R., King T.E. Jr.: Classification and Natural History of the Idiopathic Interstitial Pneumonias. Proc Am Thorac Soc, 2006, 3, 285-292.
Fireman E., Vardinon N., Burke M., Spizer S., Levin S., Endler A., Stav D., Topilsky M., Mann A., Schwarz Y., Kivity S., Greif J.: Predictive value of response to treatment of T-lymphocyte subpopulations in idiopathic pulmonary fibrosis. Eur Respir J, 1998, 11, 3, 706-711.
Kieszko R., Krawczyk P., Michnar M., Chocholska S., Milanowski J. The Yield of Endobronchial Biopsy in Pulmonary Sarcoidosis: Connection between Spirometric Impairment and Lymphocyte Subpopulations in Bronchoalveolar Lavage Fluid. Respiration, 2004, 71, 72-76.
King T.E.: Connective tissue disease. W: Interstitial Lung Disease (M.I. Schwarz, T.E. King, red.). B.C. Decker Inc. Hamilton, London 1998, 451-505.
Liebow A.: Definition and classification of interstitial pneumonias in human pathology. Prog.Respir.Dis, 1975, 8, 1-33.
Lovell D., Lindsley C., Langston C.: Lymphoid interstitial pneumonia in juvenile rheumatoid arthritis. Clinical and Laboratory observations, 1984, 105, 947-950.
Nagai S., Kitaichi M., Itoh H., Nishimura K., Izumi T., Colby TV.: Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur Respir J, 1998, 12, 5, 101-9.
Raghu G.: Interstitial Lung Disease: A Diagnostic Approach. Are CT Scan and Lung Biopsy Indicated in Every Patient?. Am J Respir Crit Care Med, 1995, 151, 909-914.
Rowińska-Zakrzewska E., Kuś J.: Choroby Układu Oddechowego Wydanie III Zmienione, Warszawa, 2004, 255-256.
Schildge J., Nagel C., Grun C.: Bronchoalveolar lavage in interstitial lung diseases: does the recovery rate affect the results?. Respiration, 2007, 74, 5, 553-557.
Shimizu Y., Tsukagoshi H., Nemoto T., Honma M., Nojima Y., Mori M.: Recurrent bronchiolitis obliterans organizing pneumonia in a patient with limited cutaneous systemic sclerosis. Rheumatol Int, 2002, 22, 5, 216-218.
Talmadge E., King Jr.: Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management, Transactions of the American Clinical and Climatological Association, vol. 2004, 115, 43-78.
Tanaka N., Kim J.S., Newell J.D., Brown K.K., Cool C.D., Meehan R., Emoto T., Matsumoto T., Lynch D.A.: Rheumatoid arthritis-related lung diseases: CT findings. Radiology, 2004, 232, 1, 81-91.
Wells A.U.: Lung disease in association with connective tissue diseases. Eur. Respir. Mon., 2000, 14, 137-164.
Wiatr E.: Definicja, klasyfikacja i patogeneza chorób śródmiąższowych. W: Choroby śródmiąższowe. Red. Rowińska-Zakrzewska E, wyd. Alfa-Medica Press, Bielsko-Biała 2001, 9-17.
Zandman-Goddard G., Tweezer-Zaks N., Shoenfeld Y.: New therapeutic strategies for systemic sclerosis-a critical analysis of the literature. Clin. Dev. Immunol., 2005, 12, 165-173.
Journals System - logo
Scroll to top